Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Increase in percent free prostate-specific antigen in men with chronic kidney disease.

BACKGROUND: Prostate-specific antigen (PSA) occurs in different molecular forms in serum: free PSA (fPSA) and complexed PSA (cPSA), the sum of which corresponds to total PSA (tPSA). In addition to tPSA, percent fPSA is widely used in the detection of prostate cancer. Free PSA, approximately 28 kDa,...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Bruun, L, Savage, C, Cronin, A, Hugosson, J, Lilja, H, Christensson, A
التنسيق:	Journal article
اللغة:	English
منشور في:	2009

مواد مشابهة

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
حسب: Bruun, L, وآخرون
منشور في: (2003)

Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen.
حسب: Christensson, A, وآخرون
منشور في: (2010)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
حسب: Christensson, A, وآخرون
منشور في: (2011)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
حسب: Bruun, L, وآخرون
منشور في: (2005)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
حسب: Vickers, A, وآخرون
منشور في: (2010)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
حسب: Bruun, L, وآخرون
منشور في: (2004)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
حسب: Becker, C, وآخرون
منشور في: (2000)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
حسب: Savage, C, وآخرون
منشور في: (2010)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
حسب: Aus, G, وآخرون
منشور في: (2004)

Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml−1
حسب: Rui Chen, وآخرون
منشور في: (2015-01-01)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
حسب: Zackrisson, B, وآخرون
منشور في: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
حسب: Becker, C, وآخرون
منشور في: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
حسب: Becker, C, وآخرون
منشور في: (2003)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
حسب: Vickers, A, وآخرون
منشور في: (2010)

The Impact of the Percent of Residual Prostate-Specific Antigen on Metastasis-Free Survival in Patients with Persistent Prostate-Specific Antigen after Radical Prostatectomy
حسب: Dan Bee Lee, وآخرون
منشور في: (2023-01-01)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
حسب: Zackrisson, B, وآخرون
منشور في: (2003)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
حسب: Aus, G, وآخرون
منشور في: (2003)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
حسب: Hugosson, J, وآخرون
منشور في: (2003)

[Isoforms of free prostate-specific antigen]
حسب: Haese, A, وآخرون
منشور في: (2004)

Isoforms of free prostate-specific antigen
حسب: Haese, A, وآخرون
منشور في: (2004)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
حسب: Vickers, A, وآخرون
منشور في: (2009)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
حسب: Nurmikko, P, وآخرون
منشور في: (2001)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.
حسب: Rui Chen, وآخرون
منشور في: (2015-01-01)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
حسب: Hugosson, J, وآخرون
منشور في: (2004)

Biology of prostate-specific antigen
حسب: Lilja, H
منشور في: (2003)

Biology of prostate-specific antigen.
حسب: Lilja, H
منشور في: (2003)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
حسب: Hugosson, J, وآخرون
منشور في: (2003)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
حسب: Aus, G, وآخرون
منشور في: (2005)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
حسب: Vickers, A, وآخرون
منشور في: (2009)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
حسب: Ulmert, D, وآخرون
منشور في: (2006)

Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function.
حسب: Ristiniemi, N, وآخرون
منشور في: (2012)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
حسب: Vickers, A, وآخرون
منشور في: (2010)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
حسب: Evans-Axelsson, S, وآخرون
منشور في: (2012)

Ratios of Free to Total Prostate-Specific Antigen and Total Prostate Specific Antigen to Protein Concentrations in Saliva and Serum of Healthy Men
حسب: Fahimeh Kamalian, وآخرون
منشور في: (2007-02-01)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
حسب: Klein, R, وآخرون
منشور في: (2012)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
حسب: Bergdahl, A, وآخرون
منشور في: (2009)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
حسب: Jeremy YC Teoh, وآخرون
منشور في: (2017-01-01)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
حسب: Zackrisson, B, وآخرون
منشور في: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
حسب: Lilja, H, وآخرون
منشور في: (2008)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
حسب: Törnblom, M, وآخرون
منشور في: (2001)